Pacira BioSciences stock surges 44% on $1.7 billion Viatris acquisition
FROM THE WIRE · FINANCE.YAHOO.COM
Viatris has agreed to acquire Pacira BioXciences, acquiring its portfolio of non-opioid pain medications. Continue Reading
Read at the source ↗MARKET IMPACTHIGH✦ News Impact agent estimateTone: expected bullishViatris's $1.7 billion acquisition of Pacira is a significant pharma sector deal.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Viatris agreed to acquire Pacira BioSciences for $1.7 billion.
- 02The acquisition includes Pacira's non-opioid pain medication portfolio.
- 03Pacira stock surged 44% following the deal announcement.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Pacira BioSciences, Inc.36.29 USD-0.04%today +44.01%Positive Viatris Inc.17.18 USD+1.06%today -1.80%Neutral
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets